# Development of a novel retinal tamponade to replace gas and oil

Tomasz P Stryjewski MD

Tallman Eye Associates Boston, Massachusetts

Retina Society 2020

# **Financial Disclosure**

Co-founder and equity co-owner with Tony Stefater MD PhD in a start-up company (Pykus Therapeutics, Inc., Cambridge, MA) which is developing the presented technology for clinical use




### **Summary**

- Gas/oil tamponade is a considerable burden for patients
- Many promising alternatives have not advanced to the clinic
- We have spent the last 5 years developing an *in situ* forming, biodegradable polymer to provide two weeks of continuous retinal tamponade
- No positioning required, no induced refractive shift, no removal surgery
- Human pilot studies to begin Q3 2020

#### **Current tamponade methods are a burden**














# Many promising alternatives have not advanced to the clinic


- Heavy silicone oils
- Magnetic oils
- Combination gas-oils
- Retinal sealants
- Intraocular capsules
- Hydrogels



# **Our Approach**

- Find really smart polymer chemists
- Design a tamponade that meets design criteria
- Test it in animals for safety and efficacy
- Manufacture in compliance with Regulatory and Quality standards of the FDA
- Perform clinical trial

# **Our Approach**



#### **PYK-1105 (functionalized PVA-PEG hydrogel)**







# **Physical Characteristics of PYK-1105**


Parameter	Result				
Time to injection (duration of minimal viscosity after mixing at 25°C)	10 min				
Time to gel formation after injection (duration until viscous gel formation at 37 °C)	4 min				
Time until degradation	11-14 days				
Refractive index	1.3385				
Transparency	>90% across visual spectrum				

# **ISO 10993 Biocompatibility Data**

 Evaluated in mice and rabbits using standard ISO protocols for evaluating biocompatibility of medical devices

Test	Result
Cytotoxicity	Non-cytotoxic
Intravitreal injection	Non-irritant
Acute systemic toxicity	Non-toxic
Material-mediated pyrogenicity	Non-pyrogenic
Endotoxin	< 0.2 EU/device
Implantation	No macroscopic reaction; minimal to no microscopic reaction
Genotoxicity	Non-mutagenic

- PYK-1105 formulation is well tolerated in a rabbit & mini-pig vitrectomy model
  - 25g vitrectomy/fluid-air exchange/PYK-1105 implantation
- Pre-GLP study in rabbit (4) & mini-pig (5)
  One pig removed from study on POD3 due to post-op VH
- Manuscript accepted for publication in *JVRD*




Representative animals from post-operative week 4

Rabbits

Pigs

	Inflammation Score (son) redness/chemosis + AC reaction + ins)					Inflammation Score (conj redness/chemosis + AC reaction + iris)					
10	P007	P0034	P0021	P0028	Notes	ID	P007	P0004	P0021	P0028	Notes
PHK-35	3	3	0		PO07/14 score for conj injection	6-2	0	0	0	0	
PHX-36	2.5	0	0	0	PO07 score for conj injection	9-2	0	0	0	0	
PHK-37	1	0	0	0	POD7 scare for conj injection	9-11	0	0	0	0	
PHK-38	¢	0	0	0		4.2	0		0	0	no PO004 exam
						89-1	0		0	0	no PO004 exam
	Vitreous Haze Score						Witneous Haze Score				
	POD/7	POD15	P0022	P0028			P007	P0054	P0031	P0028	
PHK-05	¢	0	¢	0		6-2	0	0.5	0	0	
PHK-36	0.5	0	0	0		9-2	0.5	0	0.5	0	
PHK-37	0.5	0.5	0	0		9-11	2	1	0.5	0.5	
PHK-38	0	0	0	0		4-2	0.5		0	0	no PO064 exam
						89-1	1		1	1	no PO014 exam
	Retina score (optic nerve + vasculature + retina + choroid)						Retina score (optic nerve + sasculature + retina + choroid)				
	P007	P0015	P0022	P0028	1		POD7	PODGA	P0031	P0028	
PHK-35	0	0	0	0		6-2	0	0	0	0	
PHK-36	0	0	0	0		9-2	0	0	0	0	
PHK-37	¢	0	0	0		9-11	1	0	0	0	
PHX-38	0	0	0	0		4-2	0		0	0	no PO004 exam
						89-1	Ó		ð	0	no PODD4 exam


Clinical exam scores over first month (Modified Draize/ McDonald-Shadduck scoring systems)



Post-operative week 4


post-operatively


# Normal histopath; normal ffERG




Rabbit H&E, post-operative week 4


Mini-pig H&E, post-operative week 4







photopic flash




















# Pilot human study

- 10 patient, first-in-human study to begin Q3 2020
- Multicenter, single cohort, open label study
- Enrollment restricted to patients with RRD who have limited visual potential
- Primary outcome is safety and tolerability
- Patients will be followed for 6 months post-operatively
- Interim study results expected Q1 2021

#### Team



James A. Stefater, MD, PhD President & Cofounder Vitreoretinal surgeon; Eye Heath Services

Leadership Team

Advisors



Larry Roth Product Development 20+ years experience in medical device devopment



Gordon Roberts Quality 20+ years in medical device quality and regulatory



Tomasz P. Stryjewski, MD Chief Scientific Officer & Cofounder Vitreoretinal surgeon; Tallman Eye Co-Founder, Helio Vision Inc.



Maureen O'Connell Regulatory 20+ years in ophthalmic device regulatory



Sameer Sabir Executive Chairman Founder & CEO, Brixton Founder & CEO, Seven Oaks Founder & CEO, MoMelon



Olivier Kagan Project Management Previously Director of Quality Systems at NSF



Lori Gilmartin, RN Clinical Operations 20+ years in clinical study man



Carl Awh, MD Tennessee Retina



Dean Eliott, MD Mass Eye and Ear



Leo Kim, MD, PhD Mass Eye and Ear



Darius Moshfeghi, MD Stanford

#### Contact

Tony Stefater, MD, PhD tony@pykustherapeutics.com

Tommy Stryjewski, MD tommy@pykustherapeutics.com

Pykus Therapeutics Inc. One Mifflin Place, Suite 320 Cambridge MA 02138